Yonsei Med J.
2003 Oct;44(5):800-810.
The Efficacy of High-dose Melphalan with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma
- Affiliations
-
- 1Division of Oncology-Hematology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Poong nap-dong, Songpa-gu, Seoul, Korea. csuh@amc.seoul.kr
- 2Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
- 3Department of Internal Medicine, Gyeongsang National University College of Medicine, Chinju, Korea.
Abstract
- Although high-dose therapy (HDT) with autologous hematopoietic stem cell transplantation (ASCT) is widely accepted as an effective and safe consolidation therapy for multiple myeloma (MM), few reports on its efficacy are available in Korea. We present the results of a prospective phase II study, involving 33 patients with MM treated with HDT with ASCT. The treatment consisted of 4 courses of VAD (vincristine, adriamycin, dexamethasone) induction, peripheral blood stem cell collection, and high-dose melphalan with stem cell infusion. The overall response rate was 93%, with 45% of patients having complete responses. The toxicity was predictable and tolerable. With a median follow-up of 27.6 months, the 2-year event free survival rate was 43%. At the time of writing, the median overall survival duration had not been reached with 2-year survival and projected 3-year survival rates of 81% and 74%, respectively. The overall survival was significantly better than that of the historical control patients (N=82) treated with conventional chemotherapy at our institution. The results suggest that HDT with ASCT is a valuable first or second-line treatment for patients with MM.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Complete Remission in a Patient with Multiple Myeloma after High Dose Melphalan and CD34+ Selected Autologous Transplantation
- Pre-transplant Disease Status is Important for an Improved Outcome of the Second Stem Cell Transplantation in the Myeloma Patients Receiving the First Autologous Stem Cell Transplantation
- A Case of Scleroderma following Autologous Peripheral Stem Cell Transplantation
- High Dose Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation as a First Line Treatment for Multiple Myeloma: a Korean Multicenter Study
- Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
